Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have received an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $34.50.

A number of equities research analysts have recently weighed in on CAPR shares. HC Wainwright restated a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday, November 14th. Cantor Fitzgerald upped their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Finally, Piper Sandler started coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after buying an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Capricor Therapeutics in the 3rd quarter worth approximately $3,806,000. PFM Health Sciences LP acquired a new stake in shares of Capricor Therapeutics during the 3rd quarter worth approximately $2,324,000. Renaissance Technologies LLC increased its holdings in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics in the 2nd quarter valued at $426,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Price Performance

Shares of CAPR stock opened at $13.80 on Thursday. The stock’s fifty day moving average price is $16.95 and its 200 day moving average price is $10.78. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The company has a market cap of $627.49 million, a price-to-earnings ratio of -13.02 and a beta of 3.98.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.